Table 1 Current European Medicines Agency and US Food-and-Drug Administration drug approval status for autoinflammatory diseases
| Treatment | L | European Medicines Agency (EMA) | Food-and-Drug Administration (FDA) |
|---|---|---|---|
| CAPS | |||
| Canakinumab | 1B | CINCA/NOMID, MWS and severe FCAS ≥2 years and ≥ 7.5 kg | FCAS and MWS ≥ 4 years |
| Rilonacept | 1B | none | FCAS and MWS ≥ 12 years |
| Anakinra | 2A | all CAPS patients ≥8 months and ≥ 10 kg | NOMID/CINCA only |
| TRAPS | |||
| Canakinumab | 1B | TRAPS ≥2 years and ≥ 7.5 kg | TRAPS in all adults and children |
| Anakinra | 2B | none | none |
| Etanercept | 2B | none | none |
| HIDS (MKD) | |||
| Canakinumab | 1B | MKD ≥2 years and ≥ 7.5 kg | MKD in all adults and children |
| Anakinra | 2B | none | none |
| Etanercept | 3B | none | none |
| Adalimumab | 3B | none | none |
| Tocilizumab | 4 | none | none |